Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Average Collection Period 2 year CAGR for the year ending December 31, 2023: -93.99%

Agios Pharm Average Collection Period 2 year CAGR is -93.99% for the year ending December 31, 2023. The average collection period measures the average number of days it takes for a company to collect payments from its customers. It is calculated by dividing 365 by the ratio of revenue to the average of receivables and other current assets. A lower average collection period indicates a more efficient collection process and better cash flow management, while a higher period may suggest delayed payments and potential liquidity challenges. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Agios Pharm Average Collection Period for the year ending December 31, 2022 was 527.52, a -99.26% change year over year.
Agios Pharm Average Collection Period for the year ending December 31, 2021 was 71,371.08, a 163,749.15% change year over year.
Agios Pharm Average Collection Period for the year ending December 31, 2020 was -43.61, a -171.34% change year over year.
Agios Pharm Average Collection Period for the year ending December 31, 2019 was 61.13, a 14.51% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends